Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive russian CLL study tracks Real-World treatments

NCT ID NCT05140369

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study is not testing a new drug or treatment. Instead, it will observe how doctors in Russia currently treat chronic lymphocytic leukemia (CLL) in everyday practice. About 6000 adults with CLL will be followed for up to 2 years to collect information on their health, treatments, and outcomes. The goal is to better understand real-world care patterns, not to change or compare treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 6,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

It is expected to recruit approximately 6000 patients with CLL/SLL regardless of treatment stage and line.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Ability and willing to sign the ICF * Diagnosed CLL/SLL (including watch and wait stage of disease) according to Russian clinical guides Exclusion Criteria: * Patients without CLL/SLL diagnosis * Age \<18 years * Patients who refused/did not sign the ICF

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia

Contacts and locations

Locations

  • Research Site

    Belgorod, Russia

  • Research Site

    Bryansk, Russia

  • Research Site

    Chelyabinsk, Russia

  • Research Site

    Chita, Russia

  • Research Site

    Irkutsk, Russia

  • Research Site

    Kaliningrad, Russia

  • Research Site

    Kaluga, Russia

  • Research Site

    Kazan', Russia

  • Research Site

    Kirov, Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Kurgan, Russia

  • Research Site

    Mahachkala, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Orenburg, Russia

  • Research Site

    Perm, Russia

  • Research Site

    Petropavlovsk-Kamchatskii, Russia

  • Research Site

    Petrozavodsk, Russia

  • Research Site

    Rostov-on-Don, Russia

  • Research Site

    Saint-Petesburg, Russia

  • Research Site

    Samara, Russia

  • Research Site

    Saratov, Russia

  • Research Site

    Syktyvkar, Russia

  • Research Site

    Tver', Russia

  • Research Site

    Ufa, Russia

  • Research Site

    Ulan-Ude, Russia

  • Research Site

    Vladimir, Russia

  • Research Site

    Vladivostok, Russia

  • Research Site

    Volgograd, Russia

  • Research Site

    Vologda, Russia

  • Research Site

    Yaroslavl, Russia

  • Research Site

    Yekaterinburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.